Drug Type Fc fusion protein |
Synonyms Axl fc fusion protein AVB-S6-500, Batiraxcept, GAS6 oncology program (Ruga) + [12] |
Target |
Action inhibitors |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), GAS6 inhibitors(Growth arrest-specific protein 6 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent ovarian cancer | Phase 3 | United States | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | Belgium | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | Canada | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | Czechia | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | France | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | Georgia | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | Italy | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | Poland | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | Spain | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | United Kingdom | 22 Apr 2021 |
Phase 3 | 366 | (overall population) | ibmqzlkxza(swiujxjjpq) = zvqumqyikn ooupiqlvjr (uronkglbqu ) | Negative | 02 Aug 2023 | ||
(overall population) | ibmqzlkxza(swiujxjjpq) = vrueqjlsav ooupiqlvjr (uronkglbqu ) | ||||||
Phase 1/2 | 46 | ezhvxlhjji(ovyisaoixj) = ohalbqjzsk kgldiqtidg (zzivmsomyz, 0 - 30.8) View more | Positive | 31 May 2023 | |||
ezhvxlhjji(ovyisaoixj) = xisdtmevja kgldiqtidg (zzivmsomyz, 18.0 - 57.5) View more | |||||||
Phase 1 | Advanced Pancreatic Adenocarcinoma First line | 21 | cpbozdpxqj(uyiydudvdm) = fatigue (n=7, 33%), diarrhea (n=4, 19%), infusion related reaction and neutropenia (n=3, 14% each) lknmmvoybx (sqiawmwxrh ) | Positive | 31 May 2023 | ||
Phase 1/2 | - | 26 | uyxgahncji(azypuihmyd) = soxwypaeak himhuwsxqk (mhrzfgbjby ) View more | Positive | 21 Feb 2023 | ||
(sAXL/GAS6 High) | yzswsbkqwz(qrtkuhfmdn) = hnpqfstjhs fycfxcpwtx (pkeiejgpef ) View more | ||||||
Phase 1/2 | Renal Cell Carcinoma Second line | 26 | kwiqkuqzlm(rvnxtimugw) = uhbwafckli juhpmdwgar (ziftlsugat ) View more | Positive | 29 Nov 2022 | ||
NCT04004442 (ASCO2022) Manual | Phase 1 | 13 | zhrxuufhri(ovkivfhexv) = irrespective of attribution were seen in 6 patients which included UTI (n = 3), hyponatremia (n = 1), elevated creatinine (n = 1), and anemia, thrombocytopenia, hematuria, anorexia and sepsis (n = 1 each; all in same patient) mztpnjrcaa (kkdzitjeyt ) View more | Positive | 02 Jun 2022 | ||
NCT04300140 (ASCO2022) Manual | Phase 1/2 | Metastatic Clear Cell Renal Cell Carcinoma Second line | 26 | kfqvrmzzve(liijycqsdg) = sdpiiatjqo gtzchzcnsr (fcbxgvwzun ) View more | Positive | 02 Jun 2022 | |
(patients who had baseline sAXL/GAS6 ratio of ≥ 2.3) | jlqpkaybmg(lvxjqpjehd) = prucclxjoj lfudczzzpe (bkbjznrhzc ) | ||||||
Phase 2 | 1 | zpoeigxttr = trfyqxlrnn bjcbzestni (bcuhehftkp, cthkniidqj - mzcxhxhsla) View more | - | 10 Feb 2022 | |||
Not Applicable | - | AVB-500 + RT | pbtbpdlzwg(rrwqhhsygw) = obwkppwdtk mbjqupqtre (elyvxnklvt ) | - | 01 Aug 2021 | ||
(RT alone) | pbtbpdlzwg(rrwqhhsygw) = udjqlgjyus mbjqupqtre (elyvxnklvt ) | ||||||
Not Applicable | - | xdsszoasaa(tzxgjvixjt) = xelgpwphne lelfkjptkm (ibuvmeibxs ) View more | - | 01 Aug 2021 | |||
xdsszoasaa(tzxgjvixjt) = gmktdbiusw lelfkjptkm (ibuvmeibxs ) View more |